YARW Yarrow Bioscience, Inc.

Overview and Growth

In fiscal 2025, Yarrow Bioscience, Inc. recorded $570.00K of revenue, net loss of $26.48M, and an operating cash outflow of $33.12M. Revenue of $570.00K sets the scale for evaluating how effectively sales translated into profit and cash during the year. Compared with $501.00K in fiscal 2024, revenue recorded a 13.8% year-over-year increase. The company reported diluted EPS of -$0.62, adding a shareholder-level measure to the absolute income figures considered below. A diluted share base of 42.77M links the aggregate earnings figure to diluted EPS and helps frame the per-share comparison. Compared with 42.59M diluted shares in fiscal 2024, the current 42.77M base was 0.4% higher. Total assets stood at $30.16M, showing the scale of resources supporting revenue, earnings, liquidity, and financing. Revenue equaled 0.02x of total assets, indicating how much reported top-line activity the company produced relative to its period-end asset base.

Profitability

Operations produced a $29.75M operating loss before non-operating and tax effects. The bottom-line result was a net loss of $26.48M after operating, financing, tax, and other recognized items. EBITDA was negative $29.73M, showing a deficit before interest, taxes, depreciation, and amortization. The company reported a pretax loss of $26.73M, before the effect of income taxes. Income tax expense totaled $4.00K, providing the reported tax component that separates pretax and after-tax earnings. The loss-to-equity relationship was 95.4%, placing the bottom-line deficit against shareholder capital. The loss-to-assets relationship was 87.8%, placing the bottom-line deficit against the company’s resource base. The bottom-line deficit decreased from $39.83M in fiscal 2024 to $26.48M.

Liquidity and Capital Structure

At period end, the $30.16M asset base was financed through $2.40M of liabilities and $27.77M of equity. Current assets were $30.01M against $2.40M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. At 12.53x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. The company held $24.03M in cash and equivalents, a narrower liquidity measure than total current assets. The company carried $0.00 of total debt at period end, which frames its leverage and debt-service burden. Against book equity, debt measured 0.0x, placing the company’s financial leverage in clear balance-sheet terms. Debt represented 0.0% of total assets, placing borrowing in the context of the company’s full resource base. The equity-to-assets relationship was 92.1%, placing book capital against the total resource base. Liabilities represented 7.9% of total assets, quantifying the liability-funded share of the company’s resource base. The cash-to-assets relationship was 79.7%, comparing reported cash and equivalents with the full positive asset balance. The asset base changed 54.9% from $66.91M in fiscal 2024, leaving current total assets lower year over year. Against $52.09M of equity in fiscal 2024, the current book-equity balance moved 46.7% and ended lower. The reported cash balance changed 20.6% from $19.93M in fiscal 2024, ending higher year over year.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $33.12M, rather than cash generation from operations. The company recorded a $33.12M cash deficit after capital spending for the period. Relative to total assets, the post-investment cash deficit measured 109.8%. Cash absorbed by operations decreased from $33.97M in fiscal 2024 to $33.12M.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 26, 2026.